Receptors for advanced glycosylation endproducts in human brain: Role in brain homeostasis

Molecular Medicine

Volumn 4, Issue 1, 1998, Pages 46-60

  Li, Jenny J ^a   Dickson, Dennis ^b   Hof, Patrick R ^c,d   Vlassara, Helen ^a  

^a PICOWER INST FOR MEDICAL RESEARCH   (United States)

^b MAYO CLINIC   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED PROTEIN;

AGING; ANIMAL CELL; ARTICLE; FETUS; GLIA; GLIA CELL; GLYCATION; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031918250     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401729     Document Type: Article

References (63)

1. Abraham EC, Cherian M, Smith JB. (1994) Site selectivity in the glycation of alpha a- and alpha b-crystallins hy glucose. Biochem. Biophys. Res. Commun. 201: 1451-1456.
2. Aoki Y, Yanagisawa Y, Yazaki K, Oguchi H, Kiyosawa K, Furuta S. (1992) Protective effect of vitamine supplementation on increased thermal stability of collagen in diabetic rats. Diabetologia 35: 913-916.
3. Araki N, Ueno N, Chakrabarti B, Morino Y, Horiuchi S. (1992) Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J. Biol. Chem. 267: 10211-10214.
4. Boyd-White J, Williams JC, Jr. (1996) Effect of cross-linking on matrix permeability. A model for age-modified basement membranes. Diabetes 45: 348-353.
5. Ateshkadi A, Johnson CA, Founds HW, Zimmerman SW. (1995) Serum advanced glycosylation end-products in patients on hemodialysis and capd. Perit. Dial. Int. 15: 129-133.
6. Brownlee M. (1995) Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46: 223-234.
7. Salazar R, Brandt R, Krantz S. (1995) Expression of fructosyllysine receptors on human monocytes and monocyte-like cell lines. Biochim. Biophys. Acta 1266: 57-63.
8. Sell DR, Lane MA, Johnson WA, et al. (1996) Longevity and the genetic determination of collagen glycoxidation kinetics in mammalian senescence. Proc. Natl. Acad. Sci. U.S.A. 93: 485-490.
9. Vlassara H. (1994) Serum advanced glycosylation end products: a new class of uremic toxins? Blood Purif. 12: 54-59.
10. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. (1988) Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling. Science 240: 1546-1548.
11. Smith MA, Richey PL, Taneda S, Kutty RK, Sayre LM, Monnier VM, Perry G. (1994) Advanced maillard reaction end products, free radicals, and protein oxidation in alzheimer's disease. Ann. N. Y. Acad. Sci. 738: 447-454.
12. Smith MA, Sayre LM, Monnier VM, Perry G. (1995) Radical ageing in Alzheimer's disease. Trends. Neurosci. 18: 172-176.
13. Yan SD, Chen X, Schmidt AM, et al. (1994) Glycated tau protein in Alzheimer disease: A mechanism lor induction of oxidant stress. Proc. Natl. Acad. Sci. U.S.A. 91: 7787-7791.
14. Cerami A, Vlassara H, Brownlee M. (1986) Role of nonenzymatic glycosylation in atherogenesis. J. Cell Biochem. 30: 111-120.
15. Brownlee M, Cerami A, Vlassara H. (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318: 1315-1321.
16. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. (1995) Identification of the major site of apolipoproiein b modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J. Biol. Chem. 270: 10828-10832.
17. Bucala R, Vlassara H. (1995) Advanced glycosylation end products in diabetic renal and vascular disease. Am. J. Kidney Dis. 26: 875-888.
18. Vlassara H, Bucala R. (1996) Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 45 (Suppl 3): S65-S66.
19. Vlassara H, Brownlee M, Cerami A. (1986) Non-enzymatic glycosylation: Role in the pathogenesis of diabetic complications. Clin. Chem. 32: B37-41.
20. Li JJ, Surini M, Catsicas S, Kawashima E, Bouras C. (1995) Age-dependent accumulation of advanced glycosylation end products in human neurons. Neurobiol. Aging 16: 69-76.
21. Li JJ, Voisin D, Quiquerez AL, Bouras C. (1994) Differential expression of advanced glycosylation end-products in neurons of different species. Brain Res. 641: 285-288.
22. Vitek MP, Bhattachary K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A. (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 91: 4766-4770.
23. Li Y-M, Mitsuhashi T, Wojciechowicz D, et al. (1996) Moleculr identity and cellular distribution of advanced glycation ednroduct receptors: Relationship of p60 to OST-48 and p60 to 80K-H membrane proteins. Proc. Natl. Acad. Sci. U.S.A. 93: 11047-11052.
24. Vlassara H, Brownlee M, Cerami A. (1986) Novel macrophage receptor lor glucose-modified proteins is distinct from previously described scavenger receptors. J. Exp. Med. 164: 1301-1309.
25. Vlassara H, Li Y-M, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A. (1995) Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor complex. Mol. Med. 1: 634-646.
26. Araki N, Higashi T, Mori T, et al. (1995) Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur. J. Biochem. 230: 408-415.
27. Brett J, Schmidt AM, Yan SD, et al. (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143: 1699-1712.
28. Vlassara H, Brownlee M, Cerami A. (1988) Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo. Diabetes 37: 456-461.
29. Vlassara H, Brownlee M, Cerami A. (1989) Macrophage receptor-mediated processing and regulation of advanced glycosylation endproduct (AGE)-modified proteins: Role in diabetes and aging. Prog. Clin. Biol. Res. 304: 205-218.
30. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. (1989) Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J. Exp. Med. 170: 1387-1407.
31. Abel M, Ritthaler U, Zhang Y, et al. (1995) Expression of receptors for advanced glycosylated end-products in renal disease. Nephrol. Dial. Transplant. 10: 1662-1667.
32. Saada A, Reichert F, Rotshenker S. (1996) Granulocyte macrophage colony stimulating factor produced in lesioned peripheral nerves induces the up-regulation of cell surface expression of mac-2 by macrophages and Schwann cells. J. Cell. Biol. 133: 159-167.
33. Schmidt AM, Mora R, Cao R, et al. (1994) The endothelial cell binding site for advanced glycation end products consists of a complex: an intergral membrane protein and a lactoferrin-like polypeptide. J. Biol. Chem. 269: 9882-9888.
34. Mitsuhashi T, Li Y-M, Fishbane S, Vlassara H. (1997) Depletion of reactive advanced glycation endproducts from diabetic uremic sera using alysozyme-linked matrix. J. Clin. Invest. 100: 847-854.
35. Vlassara H. (1994) AGE-receptors and in vivo biological effects of AGEs. In: Labuza TP, Reineccius G, Monnier V, O'Brien J, Baynes J (eds). Maillard Reactions in Chemistry, Food and Health. The Royal Society of Chemistry, UK. Vol. 151, pp. 254-261.
36. Mitsuhashi T, Vlassara H, Founds HW, Li Y-M. (1997) Standardizing the immunological measurement of advanced glycation endproducts using normal human serum. J. Immunol. Method 207: 79-88.
37. Vlassara H, Brownlee M, Cerami A. (1985) High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules. Proc. Natl. Acad. Sci. U.S.A. 82: 5588-5592.
38. Vlassara H, Moldawer L, Chan B. (1989) Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/ tumor necrosis factor. J. Clin. Invest. 84: 1813-1820.
39. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. (1991) Human and rat mesangial cell receptors for glucose-modified proteins: Potential role in kidney tissue remodelling and diabetic nephropathy. J. Exp. Med. 174: 931-939.
40. Merrill JE. (1992) Tumor necrosis factor-α, interleukin-1 and related cytokines in brain development: Normal and pathological. Dev. Neurosci. 14: 1-10.
41. Martinez M, Frank A, Hernanz A. (1993) Relationship of interleukin-1β and β2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type. J. Neuroimmunol. 48: 235-240.
42. Cacabelos R, Alvarez XA, Fernandez-Novoa L, et al. (1994) Brain interleukin-1β in Alzheimer's disease and vascular dementia. Methods Find. Exp. Clin. Pharmacol. 16: 141-151.
43. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. (1990) Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: Role in vascular disease of diabetes and aging. Proc. Natl. Acad. Sci. U.S.A. 87: 9010-9014.
44. Ransom BR. (1991) Vertebrate glial classification, lineage, and heterogeneity. Ann. N.Y. Acad. Sci. 633: 19-26.
45. Sabol J, He C, Stitt A, Hattori M, Vlassara H. (1997) Altered AGE receptor expression in diabetic and non-diabetic NOD kidney. Diabetes Suppl. 46: 124A.
46. He C-J, Koschinsky T, Sabol J, Buenting C, Liu C, Vlassara H. (1997) Mononuclear (MN) cell AGE receptor-1 (AGE-R1) mRNA expression and its relationship to diabetic complications. Diabetes Suppl. 46: 8A.
47. Vlassara H. (1995) Advanced glycation in diabetic renal and vascular disease. Kidney Int. Suppl. 51: S43-4.
48. Vlassara H. (1990) Advanced nonenzymatic tissue glycosylation: Cell-mediated interactions implicated in the complications associated with diabetes and aging. Blood Purif. 8: 223-232.
49. Yang Z, Makita Z, Horii Y, et al. (1991) Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: Relationship to macrophage receptor for glucose-modified proteins. J. Exp. Med. 174: 515-524.
50. Hachinski V, Munoz DG. (1997) Cerebrovascular pathology in Alzheimer's disease: Cause, effect, or epiphenomenon? Ann. N.Y. Acad. Sci. 826: 1-6.
51. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. (1994) Advanced glycosylation end-products induced glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. U.S.A. 91: 11704-11708.
52. Dickson DW, Sinicropi S, Yen S-H, et al. (1996) Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiol. Aging 17: 733-743.
53. Mattson MP, Rydel RE. (1996) Amyloid os-tox transducers. Nature 382: 674-675.
54. Yan SD, Chen X, Fu J, et al. (1996) RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691.
55. Khoury JE, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD. (1996) Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils. Nature 382: 716-719.
56. Freeman MW. (1994). Macrophage scavenger receptors. Curr. Opin. Lipidol. 5: 143-148.
57. Mrak RE, Sheng JG, Griffin WST. (1995) Glial cytokines in Alzheimer's disease. Hum. Pathol. 26: 816-824.
58. Merrill JE, Benventiste EN. (1996) Cytokine in inflammatory brain lesions: Helpful and harmful. Trends Neurosci. 19: 331-338.
59. Nitta T, Ebato M, Sato K, Okumura K. (1994) Expression of tumour necrosis factor-α, -β and interferon-γ genes within human neuroglial tumour cells and brain specimens. Cytokine 6: 171-180.
60. Kreutzberg G. (1996) Microglia: A sensor for pathological events in the CNS. Trends Neurosci. 19: 312-318.
61. Giaume C, McCarthy KD. (1996) Control of gap-junctional communication in astrocyte networks. Trends Neurosci. 19: 319-325.
62. Rozemuller JM, Eikelenboom P, Stam FC. Beyreuther K, Masters CL. (1989) A4 protein in Alzheimer's disease: Primary and secondary cellular events in extracellular amyloid deposition. J. Neuropathol. Exp. Neurol. 48: 674-691.
63. Saishoji T, Higashi T, Ikeda K, et al. (1995) Advanced glycation end products stimulate plasminogen activator activity via GM-CSF in Raw 264.7 cells. Biochem. Biophys. Res. Commun. 217: 278-285.